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Abstract The aim of this study was to compare the effect of 7 days nebulised fluticasone propionate (FP) with oral
prednisoloneon 24-hurinary-free cortisolexcretion, systemicexposure andsafety.Thiswas arandomised, double-blind,
double-dummy, two-waycrossover study.Thirty-one children (19male,12 female, mean age 8 years) with stable asthma
wererandomlyassignedto 7 days treatmentwitheither FPNebulesTM (20.5mg/2mlbd) orprednisolonetabletsonce
daily (2mg/kg/day for 4 days [maximum 40mg] followed by1mg/kg/day or half the original dose for 3 days [maximum
20mg]). After a 2^4 week washout period, patients received the second treatment for 7 days, followed by a 2-week
follow-up visit.The primary outcome measure was 24-h urinary-free cortisol concentrations corrected for creatinine.
Nebulised FP (1mgbd) had significantly less effect on 24-h urinary-free cortisol excretion than oral prednisolone
(8.9 ng/ml for FP and 5.0 ng/ml for prednisolone, P=0.001). Systemic exposure to FP was also low. In conclusion,FP Neb-
ulesTM had significantly less effect on hypothalamic^pituitary^adrenal axis function than oral prednisolone in asthmatic
childrenwhenusedatdosesrecommended for thetreatmentof anacute exacerbationof asthma.r2002 Publishedby Elsevier
Science Ltd.
doi:10.1053/rmed.2002.1323, available online at http://www.idealibrary.comon
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Current international guidelines for the management of
acute severe asthma advise treatment with high-dose
(usually nebulised) b2-agonists and a short course of sys-
temic corticosteroids (1).Oral prednisolone (1^2mg/kg/
day) is recommended for children aged 5^15 years by
the BritishGuidelines onAsthmaManagement (2). How-
ever, prednisolone given daily to children, even at low
doses (2.5^5.0mg/day), has a signi¢cant adverse e¡ect
on short-term linear growth (3) and longer-term statural
growth (4). Although hypothalamic^pituitary^adrenal
(HPA) axis function rapidly returns to normal after a sin-
gle short course of prednisolone, markers of bonemeta-
bolism can remain abnormal for several weeks (5).
Moreover, children who receive more than four courses
of systemic corticosteroid in one year, show persistently
reducedcortisol responses to Synacthen (6).The optimalReceived 3 May 2001, accepted in revised form16 January 2002.
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john.price@kcl.ac.ukdose or duration of systemic corticosteroid treatment
for acute asthma is not known, and there is striking in-
consistency in the use of systemic corticosteroids to
treat acute asthma in children, even between hospitals
in the same health region (7).
High-dose inhaled corticosteroid is a potential alter-
native to oral prednisolone in the treatment of acute
asthma attacks in children (8). Large doses of beclo-
methasone dipropionate (BDP) (9) or budesonide (10) re-
duced the severity of acute episodic asthma in children,
but therewas no reduction in hospital admission rate, or
requirement for oral corticosteroid. Fluticasone propio-
nate (FP) (1000mg/day), via metered-dose inhaler (MDI)
and spacer device, improved morning and evening peak
expiratory £ow (PEF) to a greater extent than oral pre-
dnisolone (2mg/kg/day for 4 days followed by 1mg/kg/
day for 3 days) in children presenting with an acute ex-
acerbation of asthma (11).
During an acute exacerbation of asthma lung function
is severely compromised, and it is critical that the drug is
delivered to the lung in a manner that is independent of
patients’ inspiratory £ow or co-ordination. Inhaledmed-
ication may be di⁄cult to administer by powder inhaler
626 RESPIRATORYMEDICINEor MDI when a child is acutely dyspnoeic. The use of a
nebulised corticosteroid would allow greater ease and
reliability of drug delivery to the lungs.Therefore, a neb-
ulised corticosteroid may be a suitable alternative to
oral prednisolone in the treatment of acute asthma in
children.
Recently, a nebulised formulation of FP hasbeen devel-
oped (12). FP has a favourable therapeutic ratio to those
inhaled corticosteroids already in use, due to its high to-
pical activity, high a⁄nity for the glucocorticoid recep-
tor and low oral bioavailability (13). In adults, the
estimated systemic bioavailability of nebulised FP is only
8% of the nominal dose, whereas that for budesonide is
13% with nebuliser alone (72% of dose to patient) or15%
with a Spira synchroniser (63% of dose to patient) (14). In
children (3^6 years), the systemic bioavailability of nebu-
lised budesonide is approximately half that found in
adults (6% of the nominal dose) and 26% of the dose to
patient (15).
In a previous large, double-blind, randomised, con-
trolled study in childrenwith an acute exacerbation, neb-
ulised FP (1mg for 7 days) signi¢cantly increased PEF
compared with oral prednisolone (16). However, a com-
parative assessment of the e¡ects of FP and predniso-
lone on HPA axis function was not possible, due to high
cross-reactivity of the cortisol assay with prednisolone.
Noprevious studieshave assessed the systemic e¡ects of
high-dose nebulised FP in children. In the present study,
we have compared the e¡ect of nebulised FP with oral
prednisolone on HPA axis function, measuredby a sensi-
tive assay of 24-h excretion of urinary-free cortisol in
childrenwith chronic stable asthma.
METHODS
Study design
The study had a two-centre, randomised, double-
blind, double-dummy, two-way crossover design (Fig. 1).P la c e b o  N e b u le s  b d
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FIG 1. Studydesign.A randomisation code was generated and at visit
one investigators allocated treatment numbers in
consecutive order, starting with the lowest
number available to them. Both the patient and
the investigator were blinded to treatment
allocation.
Following an initial clinic visit (Visit 1), patients
were treated on an out-patient basis and monitored
with six home or clinic visits (Visits 2^Visit 7 inclusive)
during the 4-week crossover period plus one follow-
up visit (Visit 8) (Fig. 1). The protocol was approved by
the Investigational Centre Research Ethics Committees
and conducted according to Good Clinical Practice
guidelines, in accordancewith the Declaration of Helsin-
ki. An informed consent form signed by each patient or
parent/guardian was obtained before enrolment in
the study.
Study population
Patients were eligible to take part in the study
if they met the following criteria at screening: were
aged 4^16 years inclusive; had a clinical diagnosis
of asthma in which all other chronic respiratory
diseases had been excluded; were able to use a Side-
streamTM nebuliser (Medicaid, U.K.) with parental assis-
tance if required. Inhaled corticosteroids up to
200mg/day of FP or the equivalent were permitted. Pa-
tients were excluded from the study if they had received
any systemic corticosteroids or parenteral methyl-
xanthine within 2 weeks of the screening visit, or oral/
parenteral corticosteroids for more than 7 days during
the 4 weeks before the start of the study; had been
admitted to hospital due to respiratory disease within
theprevious 2weeks; had a seriousuncontrolled disease,
or any disease likely to interfere with the objectives of
the study.V 5
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Thirty-one patients with stable asthma were enrolled
into the study and randomly assigned to one of the fol-
lowing treatment groups for 7 days:
K FP NebulesTM (2 0.5mg/2ml) bd and placebo to
match prednisolone (soluble) tablets once daily.
K Prednisolone tablets once daily: 2mg/kg/day
(maximum 40mg) for 4 days, followed by 1mg/kg/
day (maximum 20mg) or half the original dose for 3
days, and placebo to match FP NebulesTM (2 0.9%
saline/2mlbd).
There was a washout period 2^4 weeks between
treatments. The technique for nebuliser administration
was the same as that used in a previous trial of e⁄cacy
of FP Nebules (16). Nebulised medication was adminis-
tered to dryness using a mouthpiece although a mask
was permitted if the child was unable or unwilling to
use themouthpiece.Treatmentwas given twice daily, be-
tween 08.00 and 09.00 in themorning, and17.00 and19.00
in the evening. Soluble tablets were taken once daily be-
tween 08.00 and 09.00 in the morning. Patients contin-
ued to take their existing inhaled b2-agonist on an ‘as
required’ basis for relief of symptoms. After a 2^4 week
washoutperiod, subjects received the second treatment
for 7 days followedby a 2-week follow-up period.
Safetymeasures
24-h urinary-free cortisol concentrations. The 24-h urine
collection was started and completed before treatment
(day 0) and then on day 7 of each treatmentperiod.Urine
collection started on the morning of the day before the
¢rst dose (¢rst urine on rising was not collected so that
all patients started urine collection at the same time),
and ¢nished after the ¢rst urine sample on rising on
treatmentday1 (pre-dose).The secondcollection of each
treatment period started on day 7 (¢rst urine on rising
was notcollected), and ¢nished after the ¢rsturine sam-
ple on day 8.
The volume of urine was measured at the clinic and a
20ml sample was labelled, stored and frozen at 201C
until analysis. Urine samples were prepared by an auto-
mated sequential trace enrichment of dialysates system,
and separated by reverse-phase high-pressure liquid
chromatography (HPLC)with subsequent ultraviolet de-
tection of the resolved analyte (lower limit of quanti¢ca-
tion = 5ng/ml). As prednisolone is known to cross-react
with cortisol in immunoassay methods of analysis, an
HPLC assay method was used in this study, which was
validated to ensure that FP and prednisolone did not in-
terfere with the chromatographic detection of cortisol.
The reference ranges for urinary-free cortisol excretion
per day for our laboratory were 2000^27000ng/day forsubjects aged 4^12 years and 5000^55000ng/day for
subjects aged13^16 years.
Pharmacokineticmeasures.During each treatment per-
iod, a single venous blood sample was requested be-
tween days 4 and 6 inclusive. Blood sampling was not
compulsory. Patients who were unable or unwilling to
give a sample could abstain. Each patient was rando-
mised (block size=4) to have blood taken at one of four
intervals relative to the morning dose of study medica-
tion on days 4^6:
Interval1: between1h and immediately before themorn-
ing dose.
Interval 2: between 15min and 1.5h after the morning
dose.
Interval 3: between 3 and 8h after themorning dose.
Interval 4: between 9 and11h after themorning dose.
Whole blood (4ml) was drawn into a lithium^heparin
collection tube. The contents were mixed thoroughly
and centrifuged at 1500g for 10min at 41C within 2^3
hours of collection. Plasma was separated, frozen and
stored at201Cuntil analysis.Plasma sampleswere ana-
lysed in duplicate for FP using solid-phase extraction in
combination with liquid chromatography tandem mass
spectrometry (LC-MS). Plasma samples were analysed
in duplicate for prednisoloneusing solidphase extraction
in combinationwith liquid chromatography and ultravio-
let detection.Themethodhas beenvalidatedwith a low-
er limit of quanti¢cation of 20ng/ml.
Adverse events. An adverse event was de¢ned as any
untoward medical occurrence experienced by a patient
and rated as mild, moderate or severe. All adverse
events were documented.
Statistical analyses
Theprimaryendpointof this study was 24hurinary-free
cortisol concentrations adjusted for creatinine (urinary-
free cortisol concentration/creatinine concentration ng/
mg). A value of 0.55 was estimated as the residual stan-
dard deviation for log-transformedvalues of urinary-free
cortisol concentrations corrected for creatinine. Power
calculations indicated that data from 26 evaluable volun-
teers were required to detect a 35% di¡erence in the FP/
prednisolone ratio of urinary-free cortisol concentra-
tion:creatinine concentrations at the end of treatment,
at a 5% signi¢cance level, with 80% power.
Values of urinary-free cortisol corrected for creati-
ninewere log-transformed and analysedusing an analysis
of covariance, allowing for e¡ects due to subject, period,
baseline and treatment. However, a large proportion of
the urinary-free cortisol values (prior to correction for
creatinine) were below the lower limit of quanti¢cation
(BLLQ) of 5 ng/ml (15% of day 1 values and 58% of day 8
values). The post-treatment values BLLQ were likely to
be due to a treatment e¡ect, so to include them in the
628 RESPIRATORYMEDICINEanalysis, a value of 2.5 ng/ml was assigned to pre- and
post-treatment BLLQ values (mid-point of the 0^5ng/
ml range BLLQ).However, to aid interpretation, the ana-
lysis was repeated assigning low (1.50 ng/ml) and high
(4.50ng/ml) values.
It was recognised that missing pharmacokinetic data
could arise due to the inclusion of young children in the
study who may have been unwilling to provide a blood
sample, and also that many samples may have contained
FP or prednisolone concentrations BLLQ of the assay.
Pharmacokinetic parameters could not be calculated as
only two FP samples were above the assay limit of 20pg/
ml. An estimate was made of area under curve (AUC0^
24) andmaximum observedplasma concentration (Cmax).
The true Cmax could not be calculated as patients were
sampled at di¡erent times.
RESULTS
Number of patients randomised to
treatment
Thirty-one patients were randomised to treatment, 16
patients to the FP/prednisolone sequence group and 15
patients to the prednisolone/FP sequence group. There
was no signi¢cant di¡erence in baseline characteristics
between the two treatment groups (Table1).
24-h urinary-free cortisol concentrations
The pre- and post-dose urinary-free cortisol concentra-
tions are presented in Fig. 2. Four of 29 (14%) and 5 of 31
(16%) patients had a BLLQ cortisol concentration on day
0 before taking FP or prednisolone, respectively. Day 0
urinary cortisol concentrations for patients receiving FP
or prednisolone did not di¡er signi¢cantly in eitherTABLE 1. Characteristics of patients at baseline
Patientcharacteristics
Sex
Age (years)
Height (cm)
Weight (kg)
No. of patients on corticosteroids at randomization
Beclomethasone dipropionate
Budesonide
Fluticasone propionate
Median (range) pre-studycorticosteroid dose (mg bd)
Beclomethasone dipropionate
Budesonide
Fluticasone propionate
Results are expressed as themean7 SD unless otherwise stattreatment sequence, suggesting that the washout peri-
ods were long enough. However, post-treatment, only 8
of 28 (29%) patients taking FP compared with 25 of 29
(86%) patients taking prednisolone had a BLLQ cortisol
concentration.Of the eight patients taking FP who had a
BLLQ cortisol concentration post-treatment, three also
recorded BLLQ values pre-treatment.Of the 25 patients
taking prednisolone with BLLQ values post-treatment,
only four recorded BLLQ values pre-treatment. Hence,
of the subjects with quanti¢able values pre-treatment,
5/25 (20%) patients had BLLQ values after treatment
with FP compared with 21/26 (81%) patients after treat-
ment with prednisolone. There is a clear di¡erence be-
tween the treatments in the e¡ect on urinary-free
cortisol, with approximately three times as many sub-
jects having unquanti¢able cortisol concentrations after
treatment with prednisolone comparedwith FP.
In the 4^12 year age band, one subject had cortisol
o2000ng/day on Day 8 following FP and one on Day 8
followingprednisolone; one subject hadbaseline cortisol
427000ng/day and o2000ng/day on Day 8 following
FP; one subject had baseline (Day1) cortisolo2000 ng/
day for both treatment periods. In the 13^16 year age
band, one subject had baseline and Day 8 cortisol
o5000ng/day following prednisolone.
A summary of urinary-free cortisol adjusted for crea-
tinine is given inTable 2. For the purpose of analysis, a
value of 2.5 ng/mlwas given to all values BLLQ.Nebulised
FP had signi¢cantly less e¡ect on 24-hurinary-freecorti-
sol excretion comparedwith oralprednisolone (P=0.001).
Prednisolone-reduced urinary-free cortisol concentra-
tions by 61% comparedwith 34% in the FP group. An es-
timate of the ratio of treatment di¡erence (FP/
prednisolone) with associated 95% con¢dence interval
was 1.8 [1.3, 2.5]. There was an estimated 80% larger
reduction in cortisol levels after treatment withFP/prednisolone
sequence (n=16)
Prednisolone/FP
sequence (n=15)
10 male/6 female 9 male/6 female
8.772.7 7.772.6
131.3716.3 126.9714.9
30.8712.3 30.3712.8
12 (75%) 10 (67%)
5 (31%) 6 (40%)
7 (44%) 2 (13%)
0 2 (13%)
200 (50^200) 150 (100^200)
200 (50^200) 200 (200^200)
F 100 (100^100)
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FIG. 2. Twenty-four hour urinary-free cortisol in children after 7 days dosingwith nebulised £uticasone propionate (1mgbd; n=28)
ororalprednisolone (1^2mg/kg/day; n=29).Fourpatientsinthe FPgroupand ¢vepatientsintheprednisolonegrouphad 24-hurinary-
free cortisol concentrationsbelow the lowerlimitofquanti¢cationpre-dose (representedby single dotsbeneaththe dottedline ofthe
assaydetection limit).
TABLE 2. E¡ectoftreatmentwithnebulised £uticasone propionate (1mgbd) ororalprednisolone (1^2mg/kg/day) for 7 days
onurinary-free cortisol:creatinine ratio (ng:mg)
Urinary-free cortisol: creatinine ratio (ng:mg)
FPgroup (n=28)
Urinary-free cortisol: creatinine ratio (ng:mg)
Prednisolone group (n=29)
Day1 (pre-treatment) 14.0 12.8
Day 8 (7 dayspost-treatment) 9.2 5.0
Adjustedmean 8.9* 5.0
Assumingallvaluesbelow the lower limitof detection=2.5 ng/ml.
Adjusted mean: mean after taking account of covariates which were included in the statistical analysis (e.g. age, sex, centre/
country).
*P=0.001comparedwith oralprednisolone.
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FIG. 3. Plasma concentration^time pro¢les for £uticasone
propionate (*n=2) and prednisolone (!n=11) at steady state
generatedbyblood sampling in children.
SAFETYOFNEBULISEDFLUTICASONEINCHILDHOODASTHMA 629prednisolone comparedwith FPwith no evidence of car-
ry-over in the analysis (P=0.492). Additional analyses
were also performed using BLLQ values that were as-
sumed to be low (1.5ng/ml) and high (4.5ng/ml). When
values BLLQwere assumed to be1.5ng/ml, a highly signif-
icant di¡erence was observed between treatments
(Po0.0001). However, even when all values below BLLQ
were assumed to be 4.5ng/ml, a signi¢cantdi¡erence be-
tween treatments was still seen (P=0.044), with an esti-
mate of the ratio of treatment di¡erence reduced to1.3.
Plasma concentrations of £uticasone
propionate andprednisolone
Twenty-one patients provided blood samples (10 FP; 11
prednisolone). Fig 3 summarises the observed plasma
concentrations of prednisolone and FP.The observed FP
data were sparse, with an observed Cmax of 21pg/ml and
an AUC0^24 of 72.7 pgh/ml.The observed daily systemic
exposure to prednisolonewas observed Cmax 811.5ng/ml
and AUC0^24 of 2179.2ngh/ml.Adverse events
Both treatmentswerewell-tolerated,with no signi¢cant
di¡erence in the number of patientswho experienced an
adverse event during treatment (n=8 FP group; n=7 pre-
630 RESPIRATORYMEDICINEdnisolone group). Three (10%) patients experienced a
drug-related adverse event (assessedby the investigator)
during treatment with FP compared with four (13%) pa-
tients during treatment with prednisolone.The drug-re-
lated adverse events were cough (n=2 FP group; n=1
prednisolone group), throat irritation (n=2 prednisolone
group), candidiasis of the mouth/throat (n=1 predniso-
lone group) and dizziness (n=1FP group).No serious ad-
verse events were reported during the study.
DISCUSSION
This study showed that 7 days treatment with nebulised
FP (1mgbd) had signi¢cantly less e¡ect on 24-h urinary-
free cortisol excretion than oral prednisolone (2mg/kg/
day for 4 days then 1mg/kg/day for 3 days) in children
with chronic stable asthma. FP reduced the 24-h urin-
ary-free cortisol concentration by 34%, compared with
61% in the prednisolone group (assuming values BLLQ =
2.5ng/ml).
Inhaled corticosteroids have fewer systemic side-ef-
fects than oral or parenteral corticosteroids. In children
su¡ering from a severe asthmatic exacerbation, high-
dose inhaled budesonide (1600mg/day) viaTurbuhaler did
not signi¢cantly reduce serum cortisol concentrations
after1weekof treatment.However, serum cortisol con-
centrations were signi¢cantly decreased in almost all of
the children who received oral prednisolone (2mg/kg/
day), at both 0800 hours and1h after Synacthen stimula-
tion(8). Similarly, in children with moderate bronchial
asthma, inhaled FP (200mg/day) or budesonide (800mg/
day) for  4 weeks had no e¡ect on HPA axis function,
but children who received oral prednisolone showed a
marked reduction of 24-h plasma cortisol concentration
and a signi¢cantly reduced response to human cortico-
tropin releasing hormone (17).
In thepresent study, four patients in the FPgroup (14%
period 1 and 2) had urinary-free cortisol concentrations
that were BLLQ prior to study treatment on day1 com-
pared with ¢ve patients (16% period 1 and 2) in the pre-
dnisolone group. Each of the four patients with cortisol
concentrations BLLQ in the FP group were on inhaled
corticosteroids at randomisation (n=1FP100mgbd; n=1
budesonide 200mgbd; n=2BDP100mgbd), compared
with two of the ¢ve patients in the prednisolone group
(n=2BDP100mgbd). A carry-over e¡ect of nebulised FP
from the ¢rst period could potentially explain the BLLQ
urinary cortisol concentrations in the remaining three
patients in the prednisolone group. However, looking at
period1data only to eliminate anycarry-over e¡ect, two
out of four patients in the prednisolone group who had
urinary cortisol concentrations BLLQ prior to study
treatment on day one were not on inhaled corticoster-
oids atrandomisation.The low24-hurinarycortisol con-
centrations in these patients, may have been due toprevious use of inhaledor oral corticosteroidsbefore en-
rolment in the study.On the other hand, for cortisol to
appear in the urine cortisol binding globulin in the circu-
lationmustbe saturated.This requires serum concentra-
tions of at least 400nmol/l. It is therefore possible for
urine-free cortisol to be very low without adrenal sup-
pression and perhaps not surprising that some of the
pre-treatment values were low. It is also reasonable to
assume that the endogenous corticosteroid production
in these children, who were stable and well, would be
lower than in asthmatic children during an exacerbation.
Therewashowever a strikingdi¡erence in thenumber of
childrenwith cortisol levels below the limit of sensitivity
of the assay post-treatmentwith oral prednisolone com-
pared with post-treatment with nebulised £uticasone.
The response of the adrenal gland to human corticotro-
phin releasinghormonewas not assessed in this study, so
we do not know precisely the clinical relevance of our
observations.Nevertheless, our results strongly suggest
that the potential for clinically important adrenal sup-
pression is much greater after treatment with predniso-
lone than after treatmentwith nebulised £uticasone.
The present study was not powered for within group
statistical analysis, but transient e¡ects of FP on HPA
axis function are not unexpected, as they are seen with
all inhaled corticosteroids at the higher end of the re-
commended dose range. In adults, the systemic bioavail-
ability of FP is approximately two-fold less in patients
with asthma than inhealthy volunteers (13,18,19). Patients
with an acute exacerbation of asthma, therefore, may
have less systemic absorption of nebulised FP than was
observedin thepresent study inpatientswith less severe
asthma.
The secondary objective of this study was to examine
the systemic exposure to both treatments using limited
blood sampling at a point of steady-state and population
pharmacokinetics. However, only two FP samples were
above the assay limit of 20pg/ml which most likely re-
£ects the fact that FP is cleared very rapidly from the
systemic circulation by metabolism to an inactive car-
boxylic metabolite by the cytochrome P450 isoenzyme
CYP3A4 (20).
Previously published studies have demonstrated the
e⁄cacy of nebulised corticosteroids in the treatment of
acute asthma in children. Manjra and colleagues (16)
showed that nebulised FP (1mg for 7 days) signi¢cantly
increased PEF compared with oral prednisolone in chil-
dren experiencing an acute exacerbation of asthma.
Nebulised budesonide also increased the rate of recov-
ery of children presenting with an acute exacerbation of
asthma compared with oral prednisolone (21,22). These
studies con¢rm the e⁄cacy of nebulised corticosteroids
versus oral prednisolone in children with an acute ex-
acerbation of asthma, and combined with the superior
safety pro¢le of FP demonstrated in the present study,
supports an overall better therapeutic ratio for nebu-
SAFETYOFNEBULISEDFLUTICASONEINCHILDHOODASTHMA 631lised FP. The results of the present study demonstrate
that, in children with chronic stable asthma, treatment
with nebulised FP (1mgbd for 7 days) had signi¢cantly
less e¡ect on 24-h urinary-free cortisol excretion than
oral prednisolone. At these doses, FP has previously
been shown to bemore e¡ective than oral prednisolone
in the management of acute exacerbations of asthma in
children (16). In conclusion, FP NebulesTM had less e¡ect
onHPA axis function than oralprednisolone in asthmatic
childrenwhenused at doses recommended for the treat-
ment of an acute exacerbation of asthma.
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